Ausdal Financial Partners, Inc. Abb Vie Inc. Transaction History

Ausdal Financial Partners, Inc.

$897 Million
Q3 2024

A detailed history of Ausdal Financial Partners, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Ausdal Financial Partners, Inc. holds 31,631 shares of ABBV stock, worth $5.22 Million. This represents 0.7% of its overall portfolio holdings.

Number of Shares

31,631

Previous 32,087 1.42%

Holding current value

$5.22 Million

Previous $5.5 Million 13.5%

% of portfolio

0.7%

Previous 0.63%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 04, 2024	SELL	$163.84 - $199.33 $74,711 - $90,894	-456 Reduced 1.42%	31,631 $6.25 Million
Q2 2024 Aug 06, 2024	BUY	$154.79 - $180.76 $42,257 - $49,347	273 Added 0.86%	32,087 $5.5 Million
Q1 2024 Apr 12, 2024	SELL	$159.82 - $182.1 $99,088 - $112,902	-620 Reduced 1.91%	31,814 $5.79 Million
Q4 2023 Jan 11, 2024	SELL	$137.6 - $154.97 $134,022 - $150,940	-974 Reduced 2.92%	32,434 $5.03 Million
Q3 2023 Nov 08, 2023	SELL	$133.59 - $154.65 $23,645 - $27,373	-177 Reduced 0.53%	33,408 $4.98 Million
Q2 2023 Jul 31, 2023	SELL	$132.51 - $164.9 $13,781 - $17,149	-104 Reduced 0.31%	33,585 $4.52 Million
Q1 2023 May 04, 2023	SELL	$144.61 - $166.54 $226,893 - $261,301	-1,569 Reduced 4.45%	33,689 $5.37 Million
Q4 2022 Feb 03, 2023	BUY	$138.31 - $165.87 $75,378 - $90,399	545 Added 1.57%	35,258 $5.7 Million
Q3 2022 Nov 09, 2022	BUY	$134.21 - $153.93 $61,870 - $70,961	461 Added 1.35%	34,713 $4.66 Million
Q2 2022 Aug 09, 2022	SELL	$137.62 - $174.96 $124,408 - $158,163	-904 Reduced 2.57%	34,252 $5.25 Million
Q1 2022 May 04, 2022	SELL	$131.98 - $163.75 $626,905 - $777,812	-4,750 Reduced 11.9%	35,156 $5.7 Million
Q4 2021 Feb 08, 2022	SELL	$107.43 - $135.93 $2.46 Million - $3.11 Million	-22,911 Reduced 36.47%	39,906 $5.4 Million
Q3 2021 Nov 01, 2021	BUY	$106.4 - $120.78 $1.37 Million - $1.55 Million	12,846 Added 25.71%	62,817 $6.78 Million
Q2 2021 Jul 19, 2021	BUY	$105.21 - $117.21 $392,117 - $436,841	3,727 Added 8.06%	49,971 $5.63 Million
Q1 2021 May 05, 2021	BUY	$102.3 - $112.62 $1.54 Million - $1.7 Million	15,080 Added 48.39%	46,244 $5.01 Million
Q4 2020 Feb 01, 2021	BUY	$80.49 - $108.67 $78,155 - $105,518	971 Added 3.22%	31,164 $3.34 Million
Q3 2020 Nov 04, 2020	BUY	$85.91 - $100.83 $31,528 - $37,004	367 Added 1.23%	30,193 $2.65 Million
Q2 2020 Aug 06, 2020	SELL	$73.37 - $98.18 $7,263 - $9,719	-99 Reduced 0.33%	29,826 $2.93 Million
Q1 2020 May 04, 2020	SELL	$64.5 - $97.79 $66,112 - $100,234	-1,025 Reduced 3.31%	29,925 $2.51 Million
Q4 2019 Feb 14, 2020	SELL	$72.13 - $90.25 $6,996 - $8,754	-97 Reduced 0.31%	30,950 $2.58 Million
Q3 2019 Nov 19, 2019	BUY	$62.98 - $75.72 $60,523 - $72,766	961 Added 3.19%	31,047 $2.35 Million
Q2 2019 Aug 05, 2019	BUY	$65.7 - $83.98 $370,219 - $473,227	5,635 Added 23.05%	30,086 $2.02 Million
Q1 2019 May 13, 2019	BUY	$77.14 - $90.79 $878,393 - $1.03 Million	11,387 Added 87.16%	24,451 $1.97 Million
Q4 2018 Feb 11, 2019	SELL	$77.85 - $96.01 $1.29 Million - $1.59 Million	-16,593 Reduced 55.95%	13,064 $1.2 Million
Q3 2018 Nov 09, 2018	BUY	$88.91 - $98.84 $34,408 - $38,251	387 Added 1.32%	29,657 $2.81 Million
Q2 2018 Aug 08, 2018	BUY	$89.78 - $106.23 $324,105 - $383,490	3,610 Added 14.07%	29,270 $2.71 Million
Q1 2018 Apr 20, 2018	SELL	$92.01 - $123.21 $479,464 - $642,047	-5,211 Reduced 16.88%	25,660 $2.43 Million
Q4 2017 Feb 08, 2018	BUY	$89.56 - $98.21 $11,195 - $12,276	125 Added 0.41%	30,871 $2.99 Million
Q3 2017 Oct 31, 2017	BUY	$69.85 - $89.22 $2.15 Million - $2.74 Million	30,746	30,746 $2.73 Million

Others Institutions Holding ABBV

# of Institutions

3,841

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $292B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ausdal Financial Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ausdal Financial Partners, Inc. with notifications on news.

Account

Ausdal Financial Partners, Inc. Abb Vie Inc. Transaction History